The mean symptom-medication score in the active group trended lower than that in the placebo group and was improved by 27.8% and 27.9% relative to that in the placebo group during the entire pollen season and during the JCP season, respectively, but this difference did not reach statistical significance ( Fig. 3a,b ).
← all excerpts
Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial.
1
—
—